Study of post-surgery treatments for high-risk early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests different treatments after surgery for people with non-squamous lung cancer that has certain high-risk features. The goal is to find the best next step to lower the chance of the cancer coming back, based on the type of gene change in the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove all visible lung cancer (lobectomy, segmentectomy, or pneumonectomy) at stage IA or IB.
- Your tumor shows one or more high-risk features like poor differentiation or certain cell patterns.
- Your tumor has been tested for gene changes (EGFR, ALK/ROS1, or no known driver).
- Your cancer is non-squamous, not spread to the brain, and was completely removed.
- You feel well enough for daily activities (ECOG 0 or 1) and have good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of SYS6010 and an immunotherapy drug (anti-PD-(L)-1) given after surgery to prevent non-small cell lung cancer from coming back. It's for people whose cancer was removed but didn't shrink much with prior treatment before surgery.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.